全文获取类型
收费全文 | 88598篇 |
免费 | 6381篇 |
国内免费 | 1792篇 |
专业分类
耳鼻咽喉 | 930篇 |
儿科学 | 1963篇 |
妇产科学 | 1781篇 |
基础医学 | 10338篇 |
口腔科学 | 3238篇 |
临床医学 | 8572篇 |
内科学 | 19182篇 |
皮肤病学 | 1926篇 |
神经病学 | 5923篇 |
特种医学 | 1929篇 |
外国民族医学 | 6篇 |
外科学 | 11033篇 |
综合类 | 6355篇 |
现状与发展 | 2篇 |
一般理论 | 21篇 |
预防医学 | 7318篇 |
眼科学 | 1930篇 |
药学 | 6863篇 |
52篇 | |
中国医学 | 2407篇 |
肿瘤学 | 5002篇 |
出版年
2024年 | 171篇 |
2023年 | 859篇 |
2022年 | 1966篇 |
2021年 | 3827篇 |
2020年 | 2505篇 |
2019年 | 2726篇 |
2018年 | 3055篇 |
2017年 | 2476篇 |
2016年 | 2320篇 |
2015年 | 3117篇 |
2014年 | 4276篇 |
2013年 | 5074篇 |
2012年 | 7750篇 |
2011年 | 7953篇 |
2010年 | 5047篇 |
2009年 | 4303篇 |
2008年 | 5914篇 |
2007年 | 5894篇 |
2006年 | 5388篇 |
2005年 | 5003篇 |
2004年 | 4045篇 |
2003年 | 3750篇 |
2002年 | 3172篇 |
2001年 | 643篇 |
2000年 | 518篇 |
1999年 | 532篇 |
1998年 | 539篇 |
1997年 | 463篇 |
1996年 | 403篇 |
1995年 | 346篇 |
1994年 | 281篇 |
1993年 | 223篇 |
1992年 | 210篇 |
1991年 | 172篇 |
1990年 | 136篇 |
1989年 | 119篇 |
1988年 | 117篇 |
1987年 | 100篇 |
1986年 | 102篇 |
1985年 | 106篇 |
1984年 | 103篇 |
1983年 | 95篇 |
1982年 | 98篇 |
1981年 | 112篇 |
1980年 | 96篇 |
1979年 | 73篇 |
1978年 | 57篇 |
1977年 | 74篇 |
1976年 | 57篇 |
1975年 | 39篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
121.
122.
123.
Prof. Dr. Carlos Mainini 《Lung》1940,95(3-4):365-368
124.
125.
126.
David Jiménez Castro Gema Díaz David Martí Carlos Escobar Javier Ortega Sergio García-Rull Joaquin Picher Antonio Sueiro 《Blood coagulation & fibrinolysis》2007,18(2):173-177
This study aimed to determine whether a weight-adjusted dose of subcutaneous enoxaparin is as effective and safe as oral acenocoumarol for the secondary prophylaxis of pulmonary embolism. Three hundred and eighty consecutive noncancer outpatients hospitalized with an episode of symptomatic pulmonary embolism selected treatment with acenocoumarol or enoxaparin at a dose of 1 mg/kg once daily after being informed of the type of administration and expected frequency of laboratory monitoring for both medicinal products. Endpoints were symptomatic recurrent thromboembolic events evaluated by standard objective testing, and a composite endpoint of recurrent venous thromboembolism, major bleeding, and death from any cause. One hundred and ninety-nine patients (52%) chose acenocoumarol therapy and 181 chose enoxaparin monotherapy. Four patients in the enoxaparin group (2.2%) and six patients in the acenocoumarol group (3%) had an objective thromboembolic recurrence (hazard ratio, 1.35; 95% confidence interval, 0.38-4.79; P = 0.64). Nine patients in the enoxaparin group (5.0%) had a hemorrhagic complication compared with 11 in the acenocoumarol group (5.5%) (P = 0.81). The hospital length of stay was shorter with enoxaparin compared with acenocoumarol (11 versus 16 days, P = 0.0001). Enoxaparin is as effective and safe as acenocoumarol in the secondary prevention of recurrent thromboembolic disease and is associated with shorter hospitalization. 相似文献
127.
D-dimer has proved a useful diagnostic tool for the exclusion of deep venous thrombosis (DVT). The objective of this paper was to evaluate the diagnostic performance of a diagnostic algorithm combining clinical probability and D-dimer in outpatients receiving oral anticoagulant treatment (OAT) similar to those regularly applied to nonanticoagulated individuals. We enrolled 70 outpatients on OAT who presented with clinically suspected DVT; a standard diagnostic algorithm including clinical evaluation using the modified Wells score and a quantitative immunoturbidimetric D-dimer assay (STA Liatest D-Di; Diagnostica Stago, Asniéres sur Seine, France) was used. A 3-month follow-up period was applied for those patients in whom DVT was initially excluded. The prevalence of DVT was 18.5% (13/70); four of the diagnoses were made during the 3-month follow-up period. The sensitivity, specificity and negative predictive value of D-dimer were 69.2% (95 confidence interval, 42.4-87.3), 47.4% (95% confidence interval, 35.0-60.1) and 87.1% (95% confidence interval, 71.1-94.9), respectively. In conclusion, D-dimer is of limited value in outpatients on OAT presenting with clinically suspected DVT and should be omitted in such individuals; these patients should always undergo compression venous ultrasound, and repeat ultrasonography within 1 week might be warranted in cases with an initial negative examination. 相似文献
128.
129.
Robotic-assisted heller myotomy versus laparoscopic heller myotomy for the treatment of esophageal achalasia: multicenter study 总被引:3,自引:0,他引:3
Santiago Horgan M.D. Carlos Galvani M.D. Maria V. Gorodner M.D. Pablo Omelanczuck M.D. Fernando Elli M.D. Federico Moser M.D. Luis Durand M.D. Miguel Caracoche M.D. Jorge Nefa M.D. Sergio Bustos M.D. Phillip Donahue M.D. Pedro Ferraina M.D. 《Journal of gastrointestinal surgery》2005,9(8):1020-1030
Laparoscopic Heller myotomy (LHM) has become the standard treatment option for achalasia. The incidence of esophageal perforation
reported is about 5%–10%. Robotically assisted Heller myotomy (RAHM) is emerging as a safe alternative to LHM. Data comparing
the two approaches are scant. The aim of this study was to compare RAHM with LHM in terms of efficacy and safety for treatment
of achalasia. A total of 121 patients underwent surgical treatment of achalasia at three institutions. A retrospective review
of prospectively collected perioperative data was performed. Patients were divided into two groups: group A (RAHM), 59 patients,
and group B (LHM), 62 patients. All the operations were completed using minimally invasive techniques. There were 63 women
and 58 men, with a mean age of 45 ±19 years (14–82 years). Fifty-one percent of patients in group A and 95% of patients in
group B reported weight loss. Duration of symptoms was equal for both groups. Dysphagia was the main complaint in both groups
(P = NS). There was no difference in preoperative endoscopic treatment in both groups (44% versus 27%, P = NS). Operative
time was significantly shorter for LHM in the first half of the experience (141 ± 49 versus 122 ± 44 minutes, P < .05). However,
in the last 30 cases there was no difference in operative time between the groups (P = NS). Intraoperative complications (esophageal
perforation) were more frequent in group B (16% versus 0%). The incidence of postoperative heartburn did not differ by group.
There were no deaths. At 18 and 22 months, 92% and 90% of patients had relief of their dysphagia. This study suggests that
RAHM is safer than LHM, because it decreases the incidence of esophageal perforation to 0%, even in patients who had previous
treatment. At short-term follow-up, relief of dysphagia was equally achieved in both groups.
Presented at the Forty-Sixth Annual Meeting of The Society for Surgery of the Alimentary Tract, Chicago, Illinois, May 14–18,
2005 (oral presentation).
This study was supported in part by a grant provided by Intuitive Surgical, Inc. and Ethicon Endo-Surgery, Inc. 相似文献
130.
目的 观察免费板式组合药在DOTS中对合并乙肝的涂阳肺结核病人肝损害情况。方法 比较HBsAg、HBeAg、HBcAb阳性的涂阳肺结核病人与无乙肝的涂阳肺结核病人DOTS前后肝功能损害情况。结果 合并乙肝病人肝损害发生率66.3%,无乙肝者肝损害发生率8.6%,两者相比差异有显著性(P〈0.01)。22.5%病人因肝损害需更改治疗方案。结论 DOTS中合并乙肝的病人采用板式组合药用2H3R3Z3E3/4H3R3方案易发生肝损害,对这类病人应慎用常规方案,并要密切全程观察肝功能,尽可能应用肝损害较小的抗结核药。 相似文献